Moleculin Biotech (NASDAQ:MBRX) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a report released on Monday. The brokerage issued a sell rating on the stock.

Several other equities research analysts have also recently weighed in on MBRX. Roth Mkm reissued a buy rating and issued a $40.00 price objective on shares of Moleculin Biotech in a research report on Friday, April 12th. Maxim Group reduced their target price on Moleculin Biotech from $45.00 to $20.00 and set a buy rating for the company in a research report on Tuesday, March 26th.

Moleculin Biotech Trading Down 1.2 %

MBRX opened at $4.96 on Monday. Moleculin Biotech has a 1-year low of $4.28 and a 1-year high of $15.75. The stock has a market capitalization of $11.06 million, a price-to-earnings ratio of -0.36 and a beta of 1.95. The business has a 50 day moving average of $6.55 and a 200-day moving average of $7.99.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Moleculin Biotech stock. Atticus Wealth Management LLC bought a new position in Moleculin Biotech, Inc. (NASDAQ:MBRX) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 50,001 shares of the company’s stock, valued at approximately $43,000. Atticus Wealth Management LLC owned 0.17% of Moleculin Biotech at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.